Trial Profile
An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 03 Nov 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 03 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.